Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service kidney stone management cases in New Mexico: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 15 | 691 | 40% |
| 2020 | 10 | 521 | 43% |
| 2021 | 15 | 582 | 46% |
Ureteroscopy with laser lithotripsy, ESWL, PCNL. Professional codes (what the surgeon bills): CPT 52356, 52353, 52352, 50590, 50080, 50081.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 97% of the cases CMS names in New Mexico; 8 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 210 | 10,020+0.3%/yr | +0.3%/yr | 3.0 | 17% | 11,600 in 2030+2.5%/yr |
| Arizona | 76 | 3,933 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 10 | 453−21%/yr | −21%/yr | 2.00.4× | 7% | 410 in 2030−1.6%/yr |
| Hysterectomy, hysteroscopy & ablation |
Kidney stone management in every state, and its device makers · Every procedure market in New Mexico · Every state · Compare with California
| 2024 |
| 549 |
| 54% |
| 2025 est. | ≈ 560 | – |
| 2026 est. | ≈ 560 | – |
| 2022 | 12 | 563 | 50% |
| 2023 | 13 | 536 | 53% |
| 2024 | 11 | 549 | 54% |
| 2025 from claims | – | 561 453–658 | 54% |
| 2026 forecast | – | 559 438–703 | 55% |
| 2027 forecast | – | 563 417–744 | 55% |
| 2028 forecast | – | 566 401–782 | 56% |
| 2029 forecast | – | 570 387–817 | 56% |
| 2030 forecast | – | 573 375–850 | 56% |
In 2025, 17% inpatient hospital, 80% hospital outpatient, 2% surgery center. The share outside the hospital has moved +2 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| −3.7%/yr |
| 5.4 |
| 10% |
| 4,060 in 2030+0.5%/yr |
| Washington | 69 | 3,043−3.6%/yr | −3.6%/yr | 4.0 | 8% | 3,010 in 2030−0.2%/yr |
| Colorado | 50 | 2,035+0.6%/yr | +0.6%/yr | 4.2 | 23% | 2,670 in 2030+4.6%/yr |
| Oregon | 48 | 1,607−2.1%/yr | −2.1%/yr | 3.9 | 18% | 1,870 in 2030+2.6%/yr |
| Utah | 33 | 1,327−4.4%/yr | −4.4%/yr | 6.1 | 22% | 1,410 in 2030+1%/yr |
| Nevada | 26 | 1,008−3.9%/yr | −3.9%/yr | 3.5 | 24% | 1,080 in 2030+1.2%/yr |
| Idaho | 20 | 895−1%/yr | −1%/yr | 4.4 | 21% | 1,470 in 2030+8.6%/yr |
| Montana | 21 | 782−2.2%/yr | −2.2%/yr | 4.1 | 2% | 830 in 2030+1%/yr |
| Alaska | 10 | 365−1.4%/yr | −1.4%/yr | 3.0 | 18% | 400 in 2030+1.5%/yr |
| Hawaii | 7 | 297−1.8%/yr | −1.8%/yr | 2.3 | 0% | 290 in 2030−0.2%/yr |
| Wyoming | 7 | 252−3%/yr | −3%/yr | 2.3 | 18% | 260 in 2030+0.5%/yr |
| 5 |
| 427−0.8%/yr |
| −0.8%/yr |
| 2.00.9× |
| 16% |
| 400 in 2030−1.2%/yr |
| Incontinence, prolapse & sacral neuromodulation | 2 | 167−7.1%/yr | −7.1%/yr | 0.70.4× | 9% | 240 in 2030+6.5%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Calyxo leads with 87% of company spending on these surgeons in 2025, +69 pts on 2024.
In 2025, 3 companies reported engagement with New Mexico’s surgeons worth $3,616 in consulting, speaking, meals and travel tied to these products, about $329 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.